Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D8QG | ISIN: CH1242303498 | Ticker-Symbol: CR5
Stuttgart
21.11.24
21:39 Uhr
13,800 Euro
0,000
0,00 %
1-Jahres-Chart
OCULIS HOLDING AG Chart 1 Jahr
5-Tage-Chart
OCULIS HOLDING AG 5-Tage-Chart

Aktuelle News zur OCULIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.11.Oculis Holding AG - 6-K, Report of foreign issuer4
OCULIS Aktie jetzt für 0€ handeln
07.11.Oculis Holding AG: Oculis Reports Q3 2024 Financial Results and Provides Company Updates107ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial...
► Artikel lesen
21.10.Oculis (NASDAQ:OCS) Trading Up 4.8% - Here's What Happened5
21.10.Oculis Holding AG: Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees239Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts...
► Artikel lesen
15.10.Oculis Holding AG: Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 20246
02.10.Oculis Holding AG: Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer4
19.09.Oculis Holding AG: Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award4
05.09.Leerink Partners maintains Outperform tag on Oculis shares on positive portfolio update2
29.08.Oculis Holding AG: Oculis to Present at Upcoming September Investor Conferences4
28.08.Oculis Holding reports Q2 results5
28.08.Analyst maintains its target on Oculis shares post-results4
27.08.Oculis files to sell 361,011 ordinary shares for holders2
27.08.Oculis Holding AG: Oculis Publishes Consolidated Q2 Financial Statements and MD&A2
27.08.Oculis Holding AG - 6-K, Report of foreign issuer2
27.08.Oculis Holding AG: Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update255Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of...
► Artikel lesen
15.08.Oculis Appoints Dr. Sharon Klier as Chief Development Officer2
15.08.Oculis names new Chief Development Officer to bolster eye care pipeline2
15.08.Oculis Holding AG: Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer321Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage pipelineAppointment...
► Artikel lesen
30.07.Oculis Holding AG: Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference6
27.06.Oculis Holding AG: Oculis and EURETINA Announces the Ramin Tadayoni Award2
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1